TELANGANA (India CSR): Sampre Nutritions Limited, a leading confectionery manufacturer has entered into a Manufacturing Agreement with Reliance Consumer Products Limited (“RCPL”) on 8 October 2025, for manufacture and supply of nutraceutical and food products.
The agreement is expected to generate a business of Rs. 12 to 15 crores annually over a tenure of 3 years, thereby contributing significantly to the company’s revenues and supporting its nutraceutical and food product operations.
Under the agreement, SNL shall manufacture, pack, and supply confectionery products (hard-boiled confectioneries, lollipops, toffees, etc.) to RCPL in accordance with RCPL’s specifications and quality standards for further sale and distribution.
On 3rd October 2025, Sampre has considered and approved foreign currency convertible bonds (FCCBs) issue aggregating to USD 4 crore – equivalent to Rs. 355.06 crore. Company to issue 400 FCCBs of USD 1 lakh each towards subscription amount of the FCCB as per the subscription. The FCCB funds will be utilized for the purpose of broadening the global footprint of the company with emerging markets identified in Egypt and Liberia (Monrovia). This targets expansion is well designed to strengthen the Company’s presence in high-growth regions, diversify revenue streams and capture emerging opportunities in the international FMCG sectors.
Company has entered into agreement with the Lead Arranger – ARIES CAPITAL LIMITED, an investment management company appointed for the purpose of listing and underwriting the issue. The issue is in terms of the Companies Act, 2013 and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018. FCCBs will be available on the stock exchange AFRINEX EXCHANGE MAURITIUS from 10 October 2025 to 15 October 2025.
In a recent development, company has entered into a manufacturing agreement with Tolaram Wellness Ltd., Nigeria, dated August 16, 2025. Under the contract, Sampre Nutritions will manufacture and supply nutraceutical and food products to Tolaram Wellness in accordance with agreed specifications and quality standards. The agreement is expected to generate business of Rs. 10 crore annually, amounting to ~Rs. 30 crore over three years. This agreement will contribute meaningfully to Sampre’s revenues and strengthening its nutraceutical and food product operations. The contractual payment terms provide for 50% advance and the balance on dispatch; transportation will be borne by Tolaram Wellness.
In addition, the company recently signed a three-year manufacturing agreement with Rama Exports on August 19, 2025, to produce nutraceutical and food products. This contract is projected to generate Rs. 15 crore in business over its tenure, further reinforcing Sampre’s operational depth and commitment to long-term partnerships in the nutraceutical and food sector.
Recently, the company has reported remarkable financial and operational outcome for Q1FY26 that ended on June 30, 2025. For Q1FY26, the company reported Rs 10.87 crore revenue from operations, a Y-o-Y growth of 141% compared to Rs 4.51 crore revenue from operations reported in Q1FY25. Total Net Profit for Q1FY26 is reported at Rs 70.76 lakhs, a 615% Y-o-Y growth compared to Net Profit of Rs 9.89 lakhs reported in Q1FY25.
The company was also awarded the Certificate of Recognition under the India 5000 Best MSME Awards 2024 for excellence in quality, customer satisfaction, and societal impact.
(India CSR)
